Articles tagged with: Reyataz
Headline, News »
This article is the second of a two-part series on a review of Reyataz-related treatments and side effects. The first part discusses recent results on simplified Reyataz-based antiretroviral regimens; the second part discusses side effects associated with Reyataz.
A review of results from several studies on Reyataz indicates that relative to other antiretrovirals, Reyataz may be associated with fewer side effects in certain areas – such as heart problems – but more in other areas, such as kidney problems.
Results also showed that Reyataz alone was able to control…
Headline, News »
This article is the first of a two-part series on a review of Reyataz-related treatments and side effects. The first part discusses recent results on simplified Reyataz-based antiretroviral regimens; the second part discusses side effects associated with Reyataz.
A review of Reyataz-related studies at a recent conference suggests that simplified two-drug regimens using Norvir-boosted Reyataz may be as effective as three-drug regimens in patients with well-controlled HIV infection.
According to the review authors, the findings are exciting since treatment simplification and fewer side effects are likely to improve adherence…
Espanol »
Los resultados de un estudio clínico en fase 3 aún en curso indican que la pastilla de combinación conocida informalmente como “Quad”, que se toma una vez al día, es tan eficaz como el Reyataz combinado con la Truvada en las personas con VIH que no han recibido tratamiento previo.
Basándose en los resultados, el Dr. Norbert Bischofberger, vicepresidente ejecutivo de Investigación y Desarrollo y director científico de Gilead Sciences, declaró en un comunicado de prensa que Gilead comenzará a trabajar en la aprobación de la pastilla “Quad” a finales…
News »
Bristol-Myers Squibb, Gilead To Create New, Boosted Reyataz Pill – Bristol-Myers Squibb and Gilead Sciences announced an agreement last week to create a new, all-in-one boosted Reyataz (atazanavir) pill. The pill will contain Gilead Science’s investigational booster cobicistat. The combination of Reyataz and cobicistat is being evaluated in Phase 2 and Phase 3 clinical trials. Under the agreement, Bristol-Myers Squibb will be responsible for marketing the new drug. Boosting agents are used to increase the concentration of another drug in the bloodstream and allow patients to take drugs less often without losing efficacy. Currently the only antiretroviral booster approved by the U.S. Food and Drug Administration is Norvir (ritonavir). For more information, please see the press release from Bristol-Myers Squibb.
HIV Drug Patch Shows Efficacy In Preclinical Tests – Results from preclinical studies indicate that a new investigational skin patch is effective at delivering antiretroviral drugs. The patch contained a non-nucleoside reverse transcriptase inhibitor that is in early stages of development. Results showed that the patch successfully released 96 percent of the drug over seven days. The study authors stated that the skin patch could be an easier alternative to pills for people with HIV who have problems with adherence. The patch will be tested further in a Phase 1 clinical trial. For more information, please see the study abstract (pdf) and press release at the American Association of Pharmaceuticals Scientists website or the U.S. News and World Report article.
HPV Vaccine May Prevent Anal Cancer In Men Who Have Sex With Men – Results from a large international study indicate that the human papillomavirus (HPV) vaccine Gardasil effectively prevents anal pre-cancerous lesions in men who have sex with men. The study included 602 men aged 16 to 26 years old. Results showed that the vaccine reduced the rate of pre-cancerous lesions by 78 percent. To be effective the vaccine must be given before men acquire HPV, which causes most cases of anal cancer. Researchers have estimated that people with HIV are 30 to 50 times more likely to get anal cancer than people without HIV, and men who have sex with men are around 60 times more likely to get anal cancer. For more information, please see the study in the New England Journal of Medicine (abstract) or the article from Agence France-Presse.
United States Conference On AIDS Begins November 10 – The 2011 United States Conference on AIDS (USCA) will be held November 10 to 13 in Chicago. Topics covered during the conference include HIV prevention, treatment, and research as well as housing and public policy. Among the speakers are David Furnish, Chairman of the Elton John AIDS Foundation; Mondo Guerra, the HIV-positive former contestant from the television show Project Runway; and Senator Jack Jackson (AZ), a member of the President’s Advisory Council on HIV/AIDS. Over 3,000 people are expected to attend this year’s conference. For more information or to register for the conference, please see the USCA 2011 website.
Headline, News »
Results of an ongoing Phase 3 clinical trial indicate that the once-daily, combination pill known informally as the “Quad” pill is as effective as Reyataz plus Truvada in people with previously untreated HIV.
Based on the results, Dr. Norbert Bischofberger, executive vice president of Research and Development and chief scientific officer of Gilead Sciences, said in a press release that Gilead would begin working toward approval of the Quad pill by the end of the year, rather than early next year as previously stated.
“The 90 percent response rate observed…